Contract research firm IQVIA Holdings beat Wall Street estimates for fourth-quarter profit and revenue on Thursday, helped by the demand for its healthcare data and analytics services.

The 2025 forecast reflects a revenue hit of about 18% to 20% to the company's legacy portfolio from the near-term effects of generics on cancer drugs Revlimid, Pomalyst, Sprycel and Apraxane. The ...

Semiconductor testing company FormFactor (NASDAQ:FORM) in Q4 CY2024, with sales up 12.7% year on year to $189.5 million. On ...

CEO Anders Opedal announced plans to deliver more than 10% growth in oil and gas production from 2024 to 2027, supported by portfolio optimization and high-value transactions. He stated that Equinor ...

French oil major TotalEnergies beat expectations for fourth-quarter earnings on Wednesday as higher trading profits in the ...

Even though the year 2024 was not kind to certain sectors within the US economy, the broader outlook for the stock market ...

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Suzanne is a content marketer, writer ...

JioAICloud, the AI powered cloud service was launched for consumers during the quarter offering up to 100 GB of free cloud storage, while during the India Mobile Congress 2024, Jio unveiled ...

Generate a tax-free quarterly income of $103.73, amounting to $414.92 per year with this top Canadian dividend stock. Moreover, Canadians can use the TFSA (Tax-Free Savings Account) to generate ...